NRAS and neoplasm: For example, there is a subset of cutaneous melanomas with activating mutations in serine/threonine protein kinase B-Raf (BRAF) or GTPase N-Ras (NRAS), another subset with high tumor mutation burden and sensitivity to checkpoint inhibitors, or another with neither BRAF or NRAS mutations and low tumor mutation burden.